Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02822898
Other study ID # 16/15/175
Secondary ID
Status Completed
Phase Phase 4
First received June 27, 2016
Last updated August 7, 2016
Start date June 2016
Est. completion date August 2016

Study information

Verified date August 2016
Source University Hospital, Antwerp
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicines and Health Products, FAMHP
Study type Interventional

Clinical Trial Summary

The prescription of intravenous maintenance solutions - although widespread - lacks important data on the optimal sodium and potassium content, which has given rise to an important debate in the scientific literature. Our study compares two different infusion fluids in 12 healthy adult volunteers without renal failure in a single-blind randomized crossover design over two 48 hour periods during which subjects are not allowed to eat or drink. Fluid 1 is a premixed solution containing 54 mmol/L of sodium and 26 mmol/L of potassium; fluid 2 is sodium chloride 0.9% in glucose 5% with 40 mmol/L of potassium. Both solutions are administered at 25 mL/kg of ideal body weight, as recommended by current guidelines (NICE 174) and both solutions are widely used in daily clinical practice. The primary hypothesis is that isotonic maintenance solutions lead to more fluid retention than hypotonic fluids. Metabolism of both solutions is assessed by sequential analysis of urine and serum, clinical parameters and bioelectrical impedance analysis.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date August 2016
Est. primary completion date August 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Healthy adults, 18-70 years of age

- BMI 17-45 kg/m².

- Creatinine clearance >60 ml/min (according to eGFR CKD-EPI formula).

Exclusion Criteria:

- Acute medical illness within 3 weeks of first study period

- Chronic medication: under diuretic therapy or other chronic medication that interfere with urine output or induce urine retention. All chronic medication should be declared before being enrolled in the study.

- Medical history:

- cardiac failure,

- malnourishment,

- diabetes mellitus,

- urological disease preventing spontaneous or complete emptying of the bladder,

- any medical or non-medical issue preventing complaint-free fasting for 48 hours (e.g. active peptic ulcer, psychosis, substance abuse…)

- Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Drug:
NaCl 0.9% in Glucose 5% with 40mEq Potassium
NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
Glucion 5%
Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h

Locations

Country Name City State
Belgium University Hospital, Antwerp Edegem

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Antwerp Baxter Healthcare Corporation

Country where clinical trial is conducted

Belgium, 

References & Publications (2)

Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002 May 25;359(9320):1812-8. — View Citation

Moritz ML, Ayus JC. Maintenance Intravenous Fluids in Acutely Ill Patients. N Engl J Med. 2015 Oct;373(14):1350-60. doi: 10.1056/NEJMra1412877. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Osmoregulatory Profile 1: urinary volume (mL) Sequential changes in mean urinary volume (per fluid type) at T0-T12-T24-T36-T48. 48h No
Other Osmoregulatory Profile 2: urinary osmolality (mOsm/kg) Sequential changes in mean urinary osmolality (per fluid type). Urinary osmolality is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. 48h No
Other Osmoregulatory Profile 3: serum antidiuretic hormone (ADH) (pg/mL) Sequential changes in mean serum ADH (per fluid type) at T0-T24-T48. 48h No
Other Osmoregulatory Profile 4: thirst score (scale 0-5) Sequential changes in mean thirst score (per fluid type) at T0-T12-T24-T36-T48. The thirst score is a subjective score on a scale of 0-5. 48h No
Other Volume Regulatory Profile 1: urinary sodium (mmol/L) Sequential changes in mean urinary sodium (per fluid type). Urinary sodium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. Urinary sodium is used to calculate the fractional excretion of sodium. 48h No
Other Volume Regulatory Profile 2: serum aldosterone (ng/dL) Sequential changes in mean serum aldosterone (per fluid type) at T0-T24-T48. 48h No
Other Volume Regulatory Profile 3: urinary potassium (mmol/L) Sequential changes in mean urinary potassium (per fluid type). Urinary potassium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. 48h No
Other Acid-Base Profile 1: serum chloride (mmol/L) Sequential changes in mean serum chloride (per fluid type) at T0-T12-T24-T36-T48. 48h No
Other Acid-Base Profile 2: serum apparent strong ion difference (mEq/L) Sequential changes in mean serum apparent strong ion difference (per fluid type) at T0-T12-T24-T36-T48. 48h No
Other Acid-Base Profile 3: urinary anion gap (mmol/L) Sequential changes in mean urinary anion gap (per fluid type). Urinary potassium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. 48h No
Other Other Electrolytes Profile 1: Serum phosphate (mmol/L) Sequential changes in mean serum phosphate (per fluid type) at T0-T24-T48. 48h No
Other Other Electrolytes Profile 2: Red blood cell magnesium (mmol/L) Sequential changes in mean red blood cell magnesium (per fluid type) at T0-T24-T48. 48h No
Other Cortisol (µg/dL) Serum cortisol as a measure of stress due to fasting. 48h No
Other Bioelectrical impedance analysis 1: Total body water Sequential changes in mean total body water (per fluid type) at T0-T24-T48. 48h No
Other Bioelectrical impedance analysis : Extracellular volume Sequential changes in mean extracellular volume (per fluid type) at T0-T24-T48. 48h No
Primary Urine Output Urinary output over study period (as AUC). 48h No
Primary Body weight Body weight over study period (as AUC), used as a back up parameter for urinary output. 48h No
Secondary Amount of sodium retention / excretion (excreted sodium / administered sodium) Sodium retention / excretion over study period (mean at 24 and 48h) 48h No
Secondary Number of episodes of hypokalemia (<3.5 mmol/L), hyponatremia (<135 mmol/L), hypernatremia (>145 mmol/L) 48h Yes
Secondary Change of sodium level from its baseline value. Area under the electrolyte concentration curve (baseline level is reference line) 48h No
Secondary Change of sodium and potassium level from its baseline value. Area under the electrolyte concentration curve (baseline level is reference line) 48h No
See also
  Status Clinical Trial Phase
Withdrawn NCT06034899 - A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants Phase 1
Completed NCT05162274 - Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers. Phase 1
Completed NCT03748758 - Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers Phase 1
Recruiting NCT06008652 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DR-0201 in Healthy Adult Volunteers Phase 1
Terminated NCT02079480 - Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects Phase 1
Completed NCT01651325 - Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects Phase 1
Completed NCT01657838 - Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects Phase 1
Completed NCT01354379 - Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer Phase 1
Completed NCT01129466 - Effects of 2 Different Broccoli Sprout Containing Supplements on Nasal Cells in Healthy Volunteers N/A
Completed NCT04856969 - Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers Phase 1
Completed NCT01333462 - Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Phase 1
Completed NCT02942771 - A MAD Study of TT301/MW189 in Healthy Volunteers Phase 1
Completed NCT05017987 - Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 Phase 1
Not yet recruiting NCT05757596 - Study of VSA001 Injection in Chinese Healthy Adult Volunteers Phase 1
Completed NCT05074368 - Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination N/A
Completed NCT01672242 - Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®) N/A
Completed NCT03878693 - 4-methylpyrazole and Acetaminophen Metabolism Early Phase 1
Completed NCT04204772 - A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers Early Phase 1
Completed NCT05154461 - Intestinal Ketone Bodies Interfere With the Glycemic Control N/A
Active, not recruiting NCT02058472 - Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers Phase 1

External Links